New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
06:36 EDTAERIAerie Pharmaceuticals reports positive results from AR-13324 study
Aerie Pharmaceuticals announced the results of preclinical in vivo research demonstrating the ability of AR-13324 to reduce episcleral venous pressure, or EVP, in the eye. AR-13324 previously has been shown to lower intraocular pressure, or IOP, by increasing fluid outflow through the trabecular pathway, the eye's primary drain, and by reducing the production of fluid in the eye. The present study affirmed the hypothesis that AR-13324 also can lower IOP through a third mechanism of action, the reduction of EVP. This may represent a breakthrough in the lowering of IOP in patients with glaucoma and ocular hypertension.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
16:30 EDTAERITPG lowers stake in Aerie Pharmaceuticals to 8.7% from 14.5%
Subscribe for More Information
November 18, 2014
09:09 EDTAERIAerie Pharmaceuticals management to meet with Needham
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use